p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2006-12-25

AUTHORS

Kazuharu Kai, Reiki Nishimura, Nobuyuki Arima, Haruhiko Miyayama, Hirotaka Iwase

ABSTRACT

BackgroundHormone receptor status has been one of the most important factors in predicting the response to endocrine therapy in breast cancer patients. However, half of those patients with estrogen receptor-positive tumors do not respond to endocrine therapy. There have been no universal factors for predicting resistance to endocrine therapy in this population. Recently, p53 status has been extensively used as a predictive factor for response to systemic therapy, because tumor cells lacking p53 function do not respond to systemic therapy due to a failure in apoptosis. We therefore studied the relationship between the efficacy of endocrine therapy and biological factors, including p53.MethodsThe expression of p53, Ki67, and human epidermal growth factor receptor (HER)2 was examined by immunostaining in the primary tumors of 53 patients who received endocrine therapy for recurrent or advanced breast cancer. The following clinical factors were also analyzed: site treated, disease-free interval, and response to first-line endocrine therapy. To evaluate the significance of these factors, time to endocrine therapy failure (TTEF), or the total duration of sequential endocrine therapies was adopted as representing the clinical outcome.ResultsThe median TTEF was 16.1 months (range, 2.5–89.9 months). Multivariate analysis showed significantly reduced TTEF associated with no response to first-line endocrine therapy (P = 0.006 and P = 0.002 in all patients and in recurrent patients, respectively) and associated with positive p53 expression (P = 0.066 and P = 0.004, respectively).Conclusionp53 expression status was a significant molecular marker as well as the response to first-line endocrine therapy for predicting TTEF in recurrent breast cancer with hormone-sensitive disease. More... »

PAGES

426-433

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10147-006-0601-6

DOI

http://dx.doi.org/10.1007/s10147-006-0601-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1001769831

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17180510


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Hormonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cohort Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Estrogen Receptor Modulators", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunoenzyme Techniques", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Estrogen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Progesterone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Soft Tissue Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Failure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Suppressor Protein p53", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Breast and Endocrine Surgery, Kumamoto City Hospital, Kumamoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415532.4", 
          "name": [
            "Breast and Endocrine Surgery, Faculty of Medical and Pharmaceutical Science, Kumamoto University, 1-1-1 Honjo, 860-8556, Kumamoto, Japan", 
            "Breast and Endocrine Surgery, Kumamoto City Hospital, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kai", 
        "givenName": "Kazuharu", 
        "id": "sg:person.01167266271.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167266271.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Breast and Endocrine Surgery, Kumamoto City Hospital, Kumamoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415532.4", 
          "name": [
            "Breast and Endocrine Surgery, Kumamoto City Hospital, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nishimura", 
        "givenName": "Reiki", 
        "id": "sg:person.013173055502.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013173055502.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Pathology, Kumamoto City Hospital, Kumamoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415532.4", 
          "name": [
            "Clinical Pathology, Kumamoto City Hospital, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Arima", 
        "givenName": "Nobuyuki", 
        "id": "sg:person.016542450374.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016542450374.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Pathology, Kumamoto City Hospital, Kumamoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415532.4", 
          "name": [
            "Clinical Pathology, Kumamoto City Hospital, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miyayama", 
        "givenName": "Haruhiko", 
        "id": "sg:person.01312777604.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312777604.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Breast and Endocrine Surgery, Faculty of Medical and Pharmaceutical Science, Kumamoto University, 1-1-1 Honjo, 860-8556, Kumamoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.274841.c", 
          "name": [
            "Breast and Endocrine Surgery, Faculty of Medical and Pharmaceutical Science, Kumamoto University, 1-1-1 Honjo, 860-8556, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Iwase", 
        "givenName": "Hirotaka", 
        "id": "sg:person.01117473535.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117473535.84"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00311752", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000805186", 
          "https://doi.org/10.1007/bf00311752"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1385/endo:13:1:1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003856049", 
          "https://doi.org/10.1385/endo:13:1:1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1995.497", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045270804", 
          "https://doi.org/10.1038/bjc.1995.497"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm1095-1029", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017425364", 
          "https://doi.org/10.1038/nm1095-1029"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1996.6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044599284", 
          "https://doi.org/10.1038/bjc.1996.6"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2006-12-25", 
    "datePublishedReg": "2006-12-25", 
    "description": "BackgroundHormone receptor status has been one of the most important factors in predicting the response to endocrine therapy in breast cancer patients. However, half of those patients with estrogen receptor-positive tumors do not respond to endocrine therapy. There have been no universal factors for predicting resistance to endocrine therapy in this population. Recently, p53  status has been extensively used as a predictive factor for response to systemic therapy, because tumor cells lacking p53 function do not respond to systemic therapy due to a failure in apoptosis. We therefore studied the relationship between the efficacy of endocrine therapy and biological factors, including p53.MethodsThe expression of p53, Ki67, and human epidermal growth factor receptor (HER)2 was examined by immunostaining in the primary tumors of 53 patients who received endocrine therapy for recurrent or advanced breast cancer. The following clinical factors were also analyzed: site treated, disease-free interval, and response to first-line endocrine therapy. To evaluate the significance of these factors, time to endocrine therapy failure (TTEF), or the total duration of sequential endocrine therapies was adopted as representing the clinical outcome.ResultsThe median TTEF was 16.1 months (range, 2.5\u201389.9 months). Multivariate analysis showed significantly reduced TTEF associated with no response to first-line endocrine therapy (P = 0.006 and P = 0.002 in all patients and in recurrent patients, respectively) and associated with positive p53 expression (P = 0.066 and P = 0.004, respectively).Conclusionp53 expression status was a significant molecular marker as well as the response to first-line endocrine therapy for predicting TTEF in recurrent breast cancer with hormone-sensitive disease.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10147-006-0601-6", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1312225", 
        "issn": [
          "1341-9625", 
          "1437-7772"
        ], 
        "name": "International Journal of Clinical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "11"
      }
    ], 
    "keywords": [
      "first-line endocrine therapy", 
      "endocrine therapy", 
      "recurrent breast cancer", 
      "breast cancer", 
      "systemic therapy", 
      "therapy failure", 
      "significant molecular markers", 
      "expression status", 
      "estrogen receptor-positive tumors", 
      "sequential endocrine therapy", 
      "hormone-sensitive disease", 
      "human epidermal growth factor receptor", 
      "disease-free interval", 
      "advanced breast cancer", 
      "positive p53 expression", 
      "receptor-positive tumors", 
      "breast cancer patients", 
      "p53 expression status", 
      "epidermal growth factor receptor", 
      "growth factor receptor", 
      "receptor status", 
      "clinical factors", 
      "cohort study", 
      "clinical outcomes", 
      "predictive factors", 
      "cancer patients", 
      "primary tumor", 
      "p53 expression", 
      "therapy", 
      "multivariate analysis", 
      "patients", 
      "tumor cells", 
      "factor receptor", 
      "cancer", 
      "total duration", 
      "p53 function", 
      "tumors", 
      "status", 
      "molecular markers", 
      "p53", 
      "markers", 
      "failure", 
      "biological factors", 
      "response", 
      "factors", 
      "Ki67", 
      "expression", 
      "disease", 
      "recurrent", 
      "months", 
      "receptors", 
      "efficacy", 
      "outcomes", 
      "apoptosis", 
      "duration", 
      "important factor", 
      "cells", 
      "population", 
      "intervals", 
      "half", 
      "significance", 
      "study", 
      "time", 
      "resistance", 
      "function", 
      "universal factor", 
      "sites", 
      "relationship", 
      "analysis"
    ], 
    "name": "p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study", 
    "pagination": "426-433", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1001769831"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10147-006-0601-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17180510"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10147-006-0601-6", 
      "https://app.dimensions.ai/details/publication/pub.1001769831"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-06-01T22:05", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/article/article_430.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10147-006-0601-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10147-006-0601-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10147-006-0601-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10147-006-0601-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10147-006-0601-6'


 

This table displays all metadata directly associated to this object as RDF triples.

277 TRIPLES      22 PREDICATES      123 URIs      109 LITERALS      29 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10147-006-0601-6 schema:about N18a91d5205814e8297a9846ff2d1afef
2 N1c80fd3437634d58acbe5190fab8efad
3 N3157756872f8437287d3037c745703c0
4 N36d208941289446996c5aab99b36f4e0
5 N4686692defc049448551852c4b612c05
6 N4e7b9bb419494998969a17f22f48e760
7 N52f9fd27e4ed47248bc73fa1145ee1b2
8 N5e2f90b3dc1c4933aa1624718a147389
9 N6aa7f0a772504cbb8a303508d2f8ee99
10 N723e9767810c4377bcc14d842f293395
11 N76211b0b0d734ce685651543e0f28f47
12 N7d5c562fe1c945f9b9ef3836e69a48d2
13 N83fd923816304067a8962c00fc1a167d
14 N853dfb597c074a8cac687018b50136e0
15 Nbb65f62ce6b44723820676918414e5ca
16 Nc6a3fde0dc7c4fbeb0dfc015bb9dd0eb
17 Nc73246e47ad4412f93c0e1bfce64df67
18 Nd45d9f3995b744ccac4b4adb9f0d4a9b
19 Ndbead87ed8fc4f50bd67d2045ac60379
20 Nde780cd75e8241a79e6b0af69e3c262d
21 Ne9a9c1e6ca1247bf8bc1412c3ef1a91e
22 Nf0f3a9a6f1c94515ab410c34cabd3f10
23 anzsrc-for:11
24 anzsrc-for:1103
25 anzsrc-for:1112
26 schema:author Ndd445acea74f4610a3e7ce3089f80df6
27 schema:citation sg:pub.10.1007/bf00311752
28 sg:pub.10.1038/bjc.1995.497
29 sg:pub.10.1038/bjc.1996.6
30 sg:pub.10.1038/nm1095-1029
31 sg:pub.10.1385/endo:13:1:1
32 schema:datePublished 2006-12-25
33 schema:datePublishedReg 2006-12-25
34 schema:description BackgroundHormone receptor status has been one of the most important factors in predicting the response to endocrine therapy in breast cancer patients. However, half of those patients with estrogen receptor-positive tumors do not respond to endocrine therapy. There have been no universal factors for predicting resistance to endocrine therapy in this population. Recently, p53 status has been extensively used as a predictive factor for response to systemic therapy, because tumor cells lacking p53 function do not respond to systemic therapy due to a failure in apoptosis. We therefore studied the relationship between the efficacy of endocrine therapy and biological factors, including p53.MethodsThe expression of p53, Ki67, and human epidermal growth factor receptor (HER)2 was examined by immunostaining in the primary tumors of 53 patients who received endocrine therapy for recurrent or advanced breast cancer. The following clinical factors were also analyzed: site treated, disease-free interval, and response to first-line endocrine therapy. To evaluate the significance of these factors, time to endocrine therapy failure (TTEF), or the total duration of sequential endocrine therapies was adopted as representing the clinical outcome.ResultsThe median TTEF was 16.1 months (range, 2.5–89.9 months). Multivariate analysis showed significantly reduced TTEF associated with no response to first-line endocrine therapy (P = 0.006 and P = 0.002 in all patients and in recurrent patients, respectively) and associated with positive p53 expression (P = 0.066 and P = 0.004, respectively).Conclusionp53 expression status was a significant molecular marker as well as the response to first-line endocrine therapy for predicting TTEF in recurrent breast cancer with hormone-sensitive disease.
35 schema:genre article
36 schema:inLanguage en
37 schema:isAccessibleForFree false
38 schema:isPartOf N1d1db38a151b43f39c62e5430ea4f833
39 Na589a1fd9cef4e9eb0c6b9ffee165d20
40 sg:journal.1312225
41 schema:keywords Ki67
42 advanced breast cancer
43 analysis
44 apoptosis
45 biological factors
46 breast cancer
47 breast cancer patients
48 cancer
49 cancer patients
50 cells
51 clinical factors
52 clinical outcomes
53 cohort study
54 disease
55 disease-free interval
56 duration
57 efficacy
58 endocrine therapy
59 epidermal growth factor receptor
60 estrogen receptor-positive tumors
61 expression
62 expression status
63 factor receptor
64 factors
65 failure
66 first-line endocrine therapy
67 function
68 growth factor receptor
69 half
70 hormone-sensitive disease
71 human epidermal growth factor receptor
72 important factor
73 intervals
74 markers
75 molecular markers
76 months
77 multivariate analysis
78 outcomes
79 p53
80 p53 expression
81 p53 expression status
82 p53 function
83 patients
84 population
85 positive p53 expression
86 predictive factors
87 primary tumor
88 receptor status
89 receptor-positive tumors
90 receptors
91 recurrent
92 recurrent breast cancer
93 relationship
94 resistance
95 response
96 sequential endocrine therapy
97 significance
98 significant molecular markers
99 sites
100 status
101 study
102 systemic therapy
103 therapy
104 therapy failure
105 time
106 total duration
107 tumor cells
108 tumors
109 universal factor
110 schema:name p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study
111 schema:pagination 426-433
112 schema:productId N2e15814314524ab1a083f80de1708f20
113 N2fafc4cd0bb04f5c92f980b849a86fa6
114 N82ad281a606b43938252963494a08e35
115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001769831
116 https://doi.org/10.1007/s10147-006-0601-6
117 schema:sdDatePublished 2022-06-01T22:05
118 schema:sdLicense https://scigraph.springernature.com/explorer/license/
119 schema:sdPublisher Nb659c622f3c042a7821694beb32a742d
120 schema:url https://doi.org/10.1007/s10147-006-0601-6
121 sgo:license sg:explorer/license/
122 sgo:sdDataset articles
123 rdf:type schema:ScholarlyArticle
124 N18a91d5205814e8297a9846ff2d1afef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Tumor Suppressor Protein p53
126 rdf:type schema:DefinedTerm
127 N1c80fd3437634d58acbe5190fab8efad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Time Factors
129 rdf:type schema:DefinedTerm
130 N1d1db38a151b43f39c62e5430ea4f833 schema:volumeNumber 11
131 rdf:type schema:PublicationVolume
132 N2e15814314524ab1a083f80de1708f20 schema:name doi
133 schema:value 10.1007/s10147-006-0601-6
134 rdf:type schema:PropertyValue
135 N2fafc4cd0bb04f5c92f980b849a86fa6 schema:name dimensions_id
136 schema:value pub.1001769831
137 rdf:type schema:PropertyValue
138 N3157756872f8437287d3037c745703c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Prognosis
140 rdf:type schema:DefinedTerm
141 N36d208941289446996c5aab99b36f4e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Adult
143 rdf:type schema:DefinedTerm
144 N4686692defc049448551852c4b612c05 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Middle Aged
146 rdf:type schema:DefinedTerm
147 N4e7b9bb419494998969a17f22f48e760 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Estrogen Receptor Modulators
149 rdf:type schema:DefinedTerm
150 N501bf80bfc2f4cbda49a62e9077ee1dd rdf:first sg:person.01117473535.84
151 rdf:rest rdf:nil
152 N52f9fd27e4ed47248bc73fa1145ee1b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Breast Neoplasms
154 rdf:type schema:DefinedTerm
155 N5e2f90b3dc1c4933aa1624718a147389 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Immunoenzyme Techniques
157 rdf:type schema:DefinedTerm
158 N6aa7f0a772504cbb8a303508d2f8ee99 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Survival Rate
160 rdf:type schema:DefinedTerm
161 N723e9767810c4377bcc14d842f293395 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Female
163 rdf:type schema:DefinedTerm
164 N76211b0b0d734ce685651543e0f28f47 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Drug Resistance, Neoplasm
166 rdf:type schema:DefinedTerm
167 N7d5c562fe1c945f9b9ef3836e69a48d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Antineoplastic Agents, Hormonal
169 rdf:type schema:DefinedTerm
170 N82ad281a606b43938252963494a08e35 schema:name pubmed_id
171 schema:value 17180510
172 rdf:type schema:PropertyValue
173 N83fd923816304067a8962c00fc1a167d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Treatment Failure
175 rdf:type schema:DefinedTerm
176 N853dfb597c074a8cac687018b50136e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Receptors, Estrogen
178 rdf:type schema:DefinedTerm
179 Na589a1fd9cef4e9eb0c6b9ffee165d20 schema:issueNumber 6
180 rdf:type schema:PublicationIssue
181 Nb659c622f3c042a7821694beb32a742d schema:name Springer Nature - SN SciGraph project
182 rdf:type schema:Organization
183 Nbb65f62ce6b44723820676918414e5ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Aged
185 rdf:type schema:DefinedTerm
186 Nc6a3fde0dc7c4fbeb0dfc015bb9dd0eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Soft Tissue Neoplasms
188 rdf:type schema:DefinedTerm
189 Nc73246e47ad4412f93c0e1bfce64df67 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Biomarkers, Tumor
191 rdf:type schema:DefinedTerm
192 Nd45d9f3995b744ccac4b4adb9f0d4a9b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Humans
194 rdf:type schema:DefinedTerm
195 Ndbead87ed8fc4f50bd67d2045ac60379 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Bone Neoplasms
197 rdf:type schema:DefinedTerm
198 Ndd445acea74f4610a3e7ce3089f80df6 rdf:first sg:person.01167266271.39
199 rdf:rest Nf8412af2e4514901b31387648d362bd4
200 Nde780cd75e8241a79e6b0af69e3c262d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Neoplasm Recurrence, Local
202 rdf:type schema:DefinedTerm
203 Ne321fd04e3af428aa6b917f6328e89ae rdf:first sg:person.01312777604.01
204 rdf:rest N501bf80bfc2f4cbda49a62e9077ee1dd
205 Ne9a9c1e6ca1247bf8bc1412c3ef1a91e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Receptors, Progesterone
207 rdf:type schema:DefinedTerm
208 Nf0f3a9a6f1c94515ab410c34cabd3f10 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
209 schema:name Cohort Studies
210 rdf:type schema:DefinedTerm
211 Nf8412af2e4514901b31387648d362bd4 rdf:first sg:person.013173055502.44
212 rdf:rest Nffe75ab6b08b46c182376289e438d727
213 Nffe75ab6b08b46c182376289e438d727 rdf:first sg:person.016542450374.76
214 rdf:rest Ne321fd04e3af428aa6b917f6328e89ae
215 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
216 schema:name Medical and Health Sciences
217 rdf:type schema:DefinedTerm
218 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
219 schema:name Clinical Sciences
220 rdf:type schema:DefinedTerm
221 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
222 schema:name Oncology and Carcinogenesis
223 rdf:type schema:DefinedTerm
224 sg:journal.1312225 schema:issn 1341-9625
225 1437-7772
226 schema:name International Journal of Clinical Oncology
227 schema:publisher Springer Nature
228 rdf:type schema:Periodical
229 sg:person.01117473535.84 schema:affiliation grid-institutes:grid.274841.c
230 schema:familyName Iwase
231 schema:givenName Hirotaka
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117473535.84
233 rdf:type schema:Person
234 sg:person.01167266271.39 schema:affiliation grid-institutes:grid.415532.4
235 schema:familyName Kai
236 schema:givenName Kazuharu
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167266271.39
238 rdf:type schema:Person
239 sg:person.01312777604.01 schema:affiliation grid-institutes:grid.415532.4
240 schema:familyName Miyayama
241 schema:givenName Haruhiko
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312777604.01
243 rdf:type schema:Person
244 sg:person.013173055502.44 schema:affiliation grid-institutes:grid.415532.4
245 schema:familyName Nishimura
246 schema:givenName Reiki
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013173055502.44
248 rdf:type schema:Person
249 sg:person.016542450374.76 schema:affiliation grid-institutes:grid.415532.4
250 schema:familyName Arima
251 schema:givenName Nobuyuki
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016542450374.76
253 rdf:type schema:Person
254 sg:pub.10.1007/bf00311752 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000805186
255 https://doi.org/10.1007/bf00311752
256 rdf:type schema:CreativeWork
257 sg:pub.10.1038/bjc.1995.497 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045270804
258 https://doi.org/10.1038/bjc.1995.497
259 rdf:type schema:CreativeWork
260 sg:pub.10.1038/bjc.1996.6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044599284
261 https://doi.org/10.1038/bjc.1996.6
262 rdf:type schema:CreativeWork
263 sg:pub.10.1038/nm1095-1029 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017425364
264 https://doi.org/10.1038/nm1095-1029
265 rdf:type schema:CreativeWork
266 sg:pub.10.1385/endo:13:1:1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003856049
267 https://doi.org/10.1385/endo:13:1:1
268 rdf:type schema:CreativeWork
269 grid-institutes:grid.274841.c schema:alternateName Breast and Endocrine Surgery, Faculty of Medical and Pharmaceutical Science, Kumamoto University, 1-1-1 Honjo, 860-8556, Kumamoto, Japan
270 schema:name Breast and Endocrine Surgery, Faculty of Medical and Pharmaceutical Science, Kumamoto University, 1-1-1 Honjo, 860-8556, Kumamoto, Japan
271 rdf:type schema:Organization
272 grid-institutes:grid.415532.4 schema:alternateName Breast and Endocrine Surgery, Kumamoto City Hospital, Kumamoto, Japan
273 Clinical Pathology, Kumamoto City Hospital, Kumamoto, Japan
274 schema:name Breast and Endocrine Surgery, Faculty of Medical and Pharmaceutical Science, Kumamoto University, 1-1-1 Honjo, 860-8556, Kumamoto, Japan
275 Breast and Endocrine Surgery, Kumamoto City Hospital, Kumamoto, Japan
276 Clinical Pathology, Kumamoto City Hospital, Kumamoto, Japan
277 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...